GGrantIndex
← Search

ACTG A5030-PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND TRIAL OF VALGANCIC..

$19,004M01FY2004RRNIH

Mount Sinai School Of Medicine Of Nyu, New York NY

Investigators

Linked publications & trials

View original record on NIH RePORTER →